4503
Astellas Pharma Inc.
アステラス製薬
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- IFRS
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2021
1,249,528
Mar 2022
1,296,163
Mar 2023
1,518,619
Mar 2024
1,603,672
Mar 2025
1,912,323
Operating profit(million JPY)
Mar 2021
136,051
Mar 2022
155,686
Mar 2023
133,029
Mar 2024
25,518
Mar 2025
41,039
Operating profit margin(%)
Mar 2021
10.89
Mar 2022
12.01
Mar 2023
8.76
Mar 2024
1.59
Mar 2025
2.15
Profit before tax(million JPY)
Mar 2021
145,324
Mar 2022
156,886
Mar 2023
132,361
Mar 2024
24,969
Mar 2025
31,237
Profit(million JPY)
Mar 2021
120,589
Mar 2022
124,086
Mar 2023
98,714
Mar 2024
17,045
Mar 2025
50,747
Total assets(million JPY)
Mar 2021
2,273,628
Mar 2022
2,332,395
Mar 2023
2,456,518
Mar 2024
3,569,603
Mar 2025
3,339,544
Cash and cash equivalents(million JPY)
Mar 2021
326,128
Mar 2022
315,986
Mar 2023
376,840
Mar 2024
335,687
Mar 2025
188,372
Cash flows from operating activities(million JPY)
Mar 2021
306,843
Mar 2022
257,444
Mar 2023
327,767
Mar 2024
172,475
Mar 2025
194,512
Cash flows from investing activities(million JPY)
Mar 2021
-81,894
Mar 2022
-62,413
Mar 2023
-84,500
Mar 2024
-845,802
Mar 2025
-89,419
Cash flows from financing activities(million JPY)
Mar 2021
-229,479
Mar 2022
-216,298
Mar 2023
-195,623
Mar 2024
614,060
Mar 2025
-261,367
Return on equity(%)
Mar 2021
9
Mar 2022
8.7
Mar 2023
6.7
Mar 2024
1.1
Mar 2025
3.3
Equity ratio(%)
Mar 2021
61
Mar 2022
62.6
Mar 2023
61.4
Mar 2024
44.7
Mar 2025
45.3
Earnings per share(JPY per share)
Mar 2021
64.93
Mar 2022
67.08
Mar 2023
54.24
Mar 2024
9.51
Mar 2025
28.35
Net assets per share(JPY per share)
Mar 2021
748.03
Mar 2022
799.26
Mar 2023
839.26
Mar 2024
890.07
Mar 2025
845.25
Dividend per share(JPY per share)
Mar 2021
42
Mar 2022
50
Mar 2023
60
Mar 2024
70
Mar 2025
74
Payout ratio(%)
Mar 2021
64.69
Mar 2022
74.54
Mar 2023
110.62
Mar 2024
736.07
Mar 2025
261.02
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.